- HCV eradication with direct-acting antivirals (DAAs) leads to a significant reduction in insulin resistance (IR), even among patients with cirrhosis.
- IR may persist among patients with high BMI.
Why this matters
- IR is a major metabolic manifestation of HCV that favors development of steatosis and nonalcoholic fatty liver disease, risk factors for fibrosis progression and hepatocellular carcinoma.
- Prospective study of 138 patients (mean age, 58 years; 62% male) with HCV (genotype 1, 63.0%) treated with DAAs in 3 Italian tertiary-care centres.
- 68.8% were cirrhotic (Child A, 91.6%) and 29.7% were treatment-experienced.
- IR defined as homeostasis model assessment index (HOMA)-IR ≥2.5.
- Funding: None.
- 68.1% of patients had IR at baseline, which was associated with:
- Higher liver stiffness on fibroscan (23±12 vs 15±8 kPa; P<.001>
- Greater prevalence of cirrhosis (n=77 vs 18; P=.003).
- Short follow-up.